Monday, November 9, 2026

USD/EUR Bullish Momentum: 0.82% Up In The Last 5 Sessions

USD/EUR Bullish Momentum: 0.82% Up In The Last 5 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 0.82% for the last 5 sessions. At 17:07 EST on Thursday, 29 June, USD/EUR (USDEUR) is $0.92.

USD/EUR's yearly highs and lows, it's 2.075% up from its 52-week low and 12.221% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a positive 0.28%, a negative 0.09%, and a positive 0.35%, respectively.

USD/EUR's highest amplitude of average volatility was 0.30% (last week), 0.35% (last month), and 0.35% (last quarter), respectively.

News about

  • Usd/jpy trades with modest intraday losses, below 144.00 amid intervention fears. According to FXStreet on Wednesday, 28 June, "This further benefits the JPY's relative safe-haven status and contributes to the offered tone around the USD/JPY pair. ", "The USD/JPY pair comes under some selling pressure during the Asian session on Wednesday and erodes a part of the previous day's gains to levels beyond the 144.00 mark, or a fresh high since November 2022. "
  • Usd/jpy price analysis: rising wedge, Japan intervention fears prod yen pair buyers at 144.00. According to FXStreet on Wednesday, 28 June, "With this, the USD/JPY sellers remain hopeful of consolidating the biggest monthly gains since February.", "Even so, the 100-Hour Moving Average (HMA) and the one-week-old rising support line, respectively near 143.30 and 142.80 act as additional downside filters to challenge the USD/JPY bears."
  • Usd/jpy consolidates near YTD high in US upbeat data, fed’s powell and boj’s ueda eyed. According to FXStreet on Tuesday, 27 June, "After the data release, the USD/JPY extended its gains past the 144.00 mark, underpinned by the US 10-year Treasury Note, sitting at 3.772%, advanced four basis points.", "But recently, dovish comments by the Bank of Japan's (BoJ) officials aimed to keep their ultra-loose monetary policy stance, alongside an empty Japanese economic docket, suggests further USD/JPY upside is expected."
  • According to FXStreet on Tuesday, 27 June, "The Japanese Yen seems to have found some support from the above comments, as USD/JPY holds lower ground near 140.35, losing 0.10% on the day."
  • Usd/jpy: yen bulls May need to be patient – OCBC. According to FXStreet on Tuesday, 27 June, "Such activities will only serve to slow the pace of USD/JPY upticks especially if the uptrend remains intact. ", "Looking out, we expect USD/JPY to trade lower on the back of a moderate-to-soft USD profile (as Fed tightening stretches into late cycle and that USD can fall when pause or pivot comes into play) and expectation for BoJ to shift towards policy normalisation amid higher inflationary pressures in Japan."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com